Pfizer to Close Australian Neulasta Biosimilar Plant, Production Moved to Croatia


According to a report on BioPharm, pharmaceutical company, Pfizer is set to close-down the Australian plant which produces the API for HSP-130, a candidate version of Amgen’s Neulasta. Pfizer will according to the report move production to Croatia.

Pfizer according to the report will wind up operations at the facility in the Adelaide suburb Thebarton by 2021, citing existing capacity and a desire to consolidate manufacturing activities.

Currently, there are about 89 people employed at the plant but the company is expected to redeploy the staff.

The closure comes as a bit of a surprise given the fact that Pfizer had in March of 2016 announced its intention to expend about $21m in order to expand the plant in Australia for the manufacture the HSP-130.

Source: BioPharm

Be the first to comment

Leave a Reply

Your email address will not be published.